top of page
Sage Group News
Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder
Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges,...
Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment
Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single...
Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol
Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company...
Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem
Glycostem Therapeutics B.V. (“Glycostem” or the “Company”). Glycostem is a cell therapy company focused on developing stem cell-derived...
SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics
Conceptomed, an innovative Norwegian based medtech company, has created SalivaPOD™ for easy-to-use saliva sample collection. SalivaPOD™...
Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China
Sage's very exciting Chinese client, Guangzhou Doublle Bio-Product Co., Ltd., will report the results of its Chinese Phase 3 study of its...
The Sage Group Invites You to a Webinar by Axiom Space on November 30, 2021at 11 AM Eastern Time
Innovative Biological R&D in Microgravity Environments A Free Webinar You Should Not Miss! We learned of Axiom Space (Axiom Space -...
bottom of page